港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

抗疫概念

878.789

-11.619-1.30%

漲家數：3

跌家數：14

平家數：- -

市盈率：- -

高：889.460

開：889.460

低：870.070

收：890.408

成交量：3.01億

成交額：22.54億

市值：5,928.82億

流通市值：4,916.77億

資料載入中...

20%漲停效應顯現？公募調研醫藥挖出這三家雙創標的

证券市场周刊

河北一醫院工作人員先後收受商業賄賂46次，單次最大涉案金額1658萬元，持續時間最長達11年，累計涉案金額1.84億元

廣藥瞄準美妝賽道，白雲山美妝去年商品交易總額達25億元

南方都市报

股價單邊下跌20%，存倉異動後的勁方醫藥-B(02595)何時迎來反彈時刻？

藥險融合「最後一公里」商業健康險從事後報銷走向購藥場景

中国经营报

餘湧出任阿里健康董事長兼CEO

阿里健康47歲董事長兼CEO沈滌凡辭職 50歲老將餘湧接任

红星资本局

京東健康(06618)亮相2026服貿會：以全場景AI+「醫檢診藥」閉環，讓健康管理走向千家萬户

智通财经网

復星醫藥(02196.HK)周五斥2,186萬元回購134萬股

阿斯达克财经

復星醫藥(600196.SH)子公司地舒單抗生物類似藥HLX14註冊申請獲受理

復星醫藥(02196)9月11日斥資約2186.42萬港元回購134萬股

阿里健康(00241)：餘湧獲委任為董事會主席

中國生物製藥（01177）擬收購主要股東旗下公司股權以收購正大天晴5%股權涉資44.8億元

中國生物製藥(01177.HK)擬44.8億元向謝承潤收購正大天晴5%股權完成後間接持股增至65%

中國生物製藥擬以44.8億元人民幣收購正大天晴5%股權，對應市盈率19倍

同源康醫藥－Ｂ(02410)股價上升8.209%，現價港幣$2.9

阿斯达克财经

同源康醫藥-B(02410)：短期股價波動無礙長期邏輯，大股東增持疊加穩中向好基本面打開配置空間

智通财经网

京東打造中國服務第一品牌助力中國企業融入全球產業鏈

港股異動 | 創新藥概念股持續調整海外利率預期反覆 2026國談收官進入結果等待期

港股異動 | 同源康醫藥-B(02410)升逾9% 董事長增持彰顯長期發展信心創新EGFR-TKI 重磅獲批

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/BK1515/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"抗疫概念","latestPrice":878.7892,"timestamp":1789114133774,"preClose":890.4082,"halted":0,"volume":300625831,"delay":0,"changeRate":-0.013049,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-11.619019,"latestTime":"09-11 16:00:00","open":889.45984,"high":889.45984,"low":870.06995,"amount":2253603899,"amplitude":0.021776,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":1.318473,"peRate":17.086203,"turnoverRate":0.003644,"increases":3,"decrements":14,"flats":0,"marketCap":592881820352,"floatMarketCap":491676687872},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":889.45984,"amplitude":0.021776,"preClose":890.4082,"low":870.06995,"pbRate":"1.318473","latestPrice":878.7892,"volume":300625831,"delay":0,"open":889.45984,"prevYearClose":1190.107,"prevWeekClose":936.431,"prevMonthClose":925.265,"prevQuarterClose":802.777,"fiveDayClose":936.431,"twentyDayClose":912.416,"sixtyDayClose":852.523,"secType":"PLATE","market":"HK","turnoverRate":0.003644,"peRate":17.086203,"marketCap":592881820352,"floatMarketCap":491676687872,"timestamp":1789114133774,"nameCN":"抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":3,"down":14,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667852816","title":"20%漲停效應顯現？公募調研醫藥挖出這三家雙創標的","url":"https://stock-news.laohu8.com/highlight/detail?id=2667852816","media":"证券市场周刊","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667852816?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 11:11","pubTimestamp":1789269060,"startTime":"0","endTime":"0","summary":"Wind资讯显示，从6月以来公募医药基金经理的调研看，比如义翘神州、赛科希德、兴齐眼药等等。Wind资讯显示，本次调研总共有20家机构参与，其中包括了10家券商、5家私募、3家投资机构和2家公募。公司产品不直接用于临床治疗，主要是作为工具试剂，用于支持科研机构和生物医药企业的研究工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2026-09-13/doc-inirrxsh4698780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","159938","BK1574","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667683005","title":"河北一醫院工作人員先後收受商業賄賂46次，單次最大涉案金額1658萬元，持續時間最長達11年，累計涉案金額1.84億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667683005","media":"大象新闻","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667683005?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 09:18","pubTimestamp":1789262280,"startTime":"0","endTime":"0","summary":"继上海某科贸商行涉支架球囊行贿案公开曝光河北医科大学第二医院“每条支架收5000元回扣”后，仅2025年下半年，该院又涉及9件司法刑事判决。该医院工作人员先后收受商业贿赂46次，单次最大涉案金额1658万元，持续时间最长达11年，累计涉案金额1.84亿元。分析发现，超过30家医药企业长期对该医院工作人员行贿。河北祥恩医疗器械贸易有限公司为向河北医科大学第二医院销售价格虚高的医疗耗材，累计向该医院工作人员行贿2064万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-13/doc-inirrtkk4766738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LGHT","LNGR","BK1574","MEDX","AGNG","BK1161","09939","BK1583","PTH","BK1100","BK1515","RSPH","09996","IEIH","GDOC","HART","MDEV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666041345","title":"廣藥瞄準美妝賽道，白雲山美妝去年商品交易總額達25億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666041345","media":"南方都市报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666041345?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 22:07","pubTimestamp":1789222076,"startTime":"0","endTime":"0","summary":"广药集团正在瞄准美妆赛道。9月12日，由广药白云山全资子公司广州广药创赢、厦门海尼集团合资创立的广药大美丽生物科技（广州）有限公司，在穗揭牌。据悉，该公司注册地位于广州生物岛，注册资本2000万元，全面承接白云山美妆品牌自主运营业务，聚焦美妆、个护、大健康、家清四大赛道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609123872764111.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609123872764111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","BK0175","600332","BK1191","BK0097","BK1515","BK0096","BK0188","BK1197","BK1606","BK1521","BK0239","BK0012","00874","BK0070","BK0183","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666450157","title":"股價單邊下跌20%，存倉異動後的勁方醫藥-B(02595)何時迎來反彈時刻？","url":"https://stock-news.laohu8.com/highlight/detail?id=2666450157","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666450157?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 19:27","pubTimestamp":1789212439,"startTime":"0","endTime":"0","summary":"8月26日以来，劲方医药-B股价走出了一轮单边下跌行情，13个交易日内累跌幅度近20%。在板块回调趋势下，导致劲方医药同期股价跑输板块的原因或在于即将到来的公司大股东减持。盘面表现上，劲方医药近日股价累跌近20%的直接原因显然在于9月19日的新一轮解禁潮。而对劲方医药股价构成实际短期负面压力的原因则在于一笔存仓异动。香港联交所资料显示，9月3日，劲方医药)出现存仓异动，存仓市值总计19.55亿港元，占比19.65%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1515","BK1574","09939","BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666506094","title":"藥險融合「最後一公里」 商業健康險從事後報銷走向購藥場景","url":"https://stock-news.laohu8.com/highlight/detail?id=2666506094","media":"中国经营报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666506094?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 16:46","pubTimestamp":1789202815,"startTime":"0","endTime":"0","summary":"过去10年，我国商业健康保险年均增速超过20%。然而，结构性矛盾也集中显现。面对医药费用负担重、用药开支大、保险投保约束多、理赔流程繁琐等现实难题，商业健康险该如何破解？2025年，国家金融监督管理总局发布《关于推动健康保险高质量发展的指导意见》（以下简称《指导意见》），明确提出“积极将医疗新技术、新药品、新器械纳入保险保障范围”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609123872728622.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609123872728622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1589","LU2213484517.USD","LU2399975544.HKD","BK4220","LU0244354667.USD","09618","LU1655091616.SGD","BK4558","LU1580142542.USD","BK4503","LU1781817850.SGD","BK0183","LU2495084118.USD","LU0456827905.SGD","BK1142","SGXZ62798434.SGD","IE00BGV7N243.SGD","SG9999002463.SGD","LU1997244956.HKD","LU1820825898.SGD","BK4585","KJD","LU0326950275.SGD","BK0028","BK1583","BK1571","BK4614","LU1997245177.USD","BK0012","LU1961090484.USD","LU1064131003.USD","BK4526","BK4524","LU0106959298.USD","BK0175","SGXZ86797644.SGD","LU0210526637.USD","HK0000320223.HKD","LU0117841782.USD","LU0039217434.USD","BK0207","JD","BK1247","LU1146622755.USD","LU0051755006.USD","HK0000306701.USD","LU1720050803.USD","LU2328871848.SGD","LU0463099449.HKD","IE0005HP3H50.USD","BK4531","BK4122","HK0000320264.USD","HK0000181138.USD","LU1064130708.USD","06618","LU0047713382.USD","LU0231483743.USD","LU1255011170.USD","LU1188198961.HKD","BK4504","LU2148510915.USD","BK4588","LU1688375341.USD","LU1934453819.USD","BK0196","BK4551","BK1591","BK4509","IE0008368742.USD","LU1997245094.SGD","BK4579","LU1969619763.USD","86618","LU0307460666.USD","LU0456846285.SGD","HK0000181112.HKD","LU1880383366.USD","PNGAY","LU1794554557.SGD","LU0405327148.USD","601318","02318","BK1515","LU0588546209.SGD","HK0000306685.HKD","BK1615","BK0188","BK0070","LU0405327494.USD","BK0032","LU2289578879.USD","LU1979443071.USD","BK4505","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666657838","title":"餘湧出任阿里健康董事長兼CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2666657838","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666657838?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 22:12","pubTimestamp":1789135920,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！（来源：红星新闻）▲余涌 据阿里巴巴国际站红星资本局获悉，沈涤凡还将在阿里集团内辅助吴泳铭进行人工智能在生物医疗领域的探索。公开资料显示，余涌于2005年加入阿里巴巴，在消费和电子商务领域深耕超过20年，在商家运营、供应链改造等方面有丰富经验。阿里健康增长稳健，截至2026年3月31日止财年，公司收入342.55亿元，同比增长12%；净利润19.36亿元，同比增长35.2%。红星新闻记者 杨佩雯编辑 郭庄审核 何先菊","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/t/2026-09-11/doc-inirnnxw5668378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1584","BK1247","BK1515","BK1589","BK1610","BK1189","HK0000165453.HKD","BK1142","BK1502","BK1617","BK1501","BK1591","00241","BK1571","BK1615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666052416","title":"阿里健康47歲董事長兼CEO沈滌凡辭職 50歲老將餘湧接任","url":"https://stock-news.laohu8.com/highlight/detail?id=2666052416","media":"红星资本局","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666052416?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 20:15","pubTimestamp":1789128918,"startTime":"0","endTime":"0","summary":"红星资本局9月11日消息，当天，阿里健康公告高层发生人事变动。公告称，自2026年9月11日起，余涌已获委任为公司执行董事、董事会主席、首席执行官、提名委员会主席，以及根据联交所证券上市规则第3.05条规定的公司授权代表(“授权代表”)。董事会进一步公布，沈涤凡已辞任董事会主席、首席执行官、提名委员会主席及授权代表，自2026年9月11日营业时间结束时起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609113872252591.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609113872252591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1584","HK0000165453.HKD","BK1142","BK1615","BK1501","BK1189","BK1591","BK1610","BK1617","BK1571","BK1502","BK1515","00241","BK1589","BK1247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666529659","title":"京東健康(06618)亮相2026服貿會：以全場景AI+「醫檢診藥」閉環，讓健康管理走向千家萬户","url":"https://stock-news.laohu8.com/highlight/detail?id=2666529659","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666529659?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 18:52","pubTimestamp":1789123979,"startTime":"0","endTime":"0","summary":"作为京东集团专注医疗健康业务的子集团，京东健康(06618)在现场展示了“医检诊药”服务闭环、全场景AI+应用落地，以及出海企业健康保障等最新实践，吸引不少现场观众体验。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260911/20260911185354_30071.png?x-oss-process=image/format,jpg/quality,q_60","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260911/20260911185354_30071.png?x-oss-process=image/format,jpg/quality,q_60"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495142.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["VTHR","BK1247","AIPO","LU0456827905.SGD","BK1571","BK1589","BK1615","BK1591","CHAT","AGIX","ARTY","LU0051755006.USD","BK1515","SGXZ62798434.SGD","BK1142","BK1583","86618","QTOC","SGXZ86797644.SGD","06618"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666258523","title":"復星醫藥(02196.HK)周五斥2,186萬元回購134萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666258523","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666258523?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 17:49","pubTimestamp":1789120140,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，于9月11日回购134万股，每股作价介乎16.14至16.5元，涉资约2,186.42万元。(da)(港股报价延迟最少十五分钟。沽空资料截至 2026-09-11 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250731211503309_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250731211503309_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544114/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544114/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0028","BK0175","BK1191","BK0012","BK0060","BK0239","BK0187","BK0096","600196","02196","BK0196","BK1515","BK0183","BK0188","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666235705","title":"復星醫藥(600196.SH)子公司地舒單抗生物類似藥HLX14註冊申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666235705","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666235705?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 17:44","pubTimestamp":1789119840,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的地舒单抗生物类似药HLX14120mg/瓶规格的药品注册申请获国家药品监督管理局受理。此次申报适应症为其参照药安加维于中国境内已获批上市的所有适应症。据悉，HLX14为公司自主研发的地舒单抗生物类似药。截至公告日期，HLX14已分别于美国、欧盟、英国、加拿大获批上市。截至2026年8月，公司现阶段针对HLX14的累计研发投入约为3.52亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600196","PPH","BK0188","LU2272731865.HKD","BK4585","LU2473716301.USD","BK0187","BK0196","IE00B5TLWC47.USD","LU2272731782.SGD","XPH","BK1191","BK0175","BK0012","LU1992135399.USD","BK0096","02196","BK0183","BK0028","IBB","LU1992135472.HKD","BK0060","LU2322448957.HKD","LU2322448791.USD","BK1515","BK0239","BK4588","BK1593","LU2272731600.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666528460","title":"復星醫藥(02196)9月11日斥資約2186.42萬港元回購134萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666528460","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666528460?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 17:36","pubTimestamp":1789119362,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，于2026年9月11日该公司斥资约2186.42万港元回购134万股，回购价格为每股16.14至16.5港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK0187","600196","BK0028","BK1515","BK0239","02196","BK0188","BK0196","BK0012","BK0096","BK1593","BK0175","BK0183","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666528657","title":"阿里健康(00241)：餘湧獲委任為董事會主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2666528657","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666528657?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 17:29","pubTimestamp":1789118994,"startTime":"0","endTime":"0","summary":"智通财经APP讯，阿里健康(00241)发布公告，下列事项自2026年9月11日营业时间结束时起生效：(i)余涌先生已获委任为公司执行董事、董事会主席、首席执行官、提名委员会主席，以及根据香港联合交易所有限公司证券上市规则第3.05条规定的公司授权代表;及(ii)沈涤凡先生已辞任主席、首席执行官、提名委员会主席及授权代表。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495029.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿里健康(00241)：余涌获委任为董事会主席","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1142","HK0000165453.HKD","BK1501","BK1247","BK1515","00241","BK1584","BK1591","BK1617","BK1571","BK1610","BK1615","BK1502","BK1589","BK1189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666540438","title":"中國生物製藥（01177）擬收購主要股東旗下公司股權以收購正大天晴5%股權 涉資44.8億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666540438","media":"金吾财讯","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666540438?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 17:11","pubTimestamp":1789117861,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国生物制药（01177）发布公告，公司拟通过向主要股东收购Sino Harmony Ventures Limited雍华创投有限公司的股权，以收购正大天晴5%股权，代价为44.8亿元人民币。正大天晴为公司的附属公司，于交割时，公司间接持有正大天晴的股权将由60%增加至65%。以2026年6月底正大天晴LTM经调整归母净利润计，可增厚集团经调整归母净利润约7.4%（即约3.5亿人民币）。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/YThlNWYyZDkwZDI4NjgyMzY1OTg4MDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YThlNWYyZDkwZDI4NjgyMzY1OTg4MDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991444","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YR35.GBP","HK0000165453.HKD","BK1521","BK1515","01177","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1191","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666547461","title":"中國生物製藥(01177.HK)擬44.8億元向謝承潤收購正大天晴5%股權 完成後間接持股增至65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666547461","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666547461?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 16:37","pubTimestamp":1789115835,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01177","BK1515","IE00BZ08YT58.USD","BK1191","BK1521","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","BK1589","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164324018","title":"中國生物製藥擬以44.8億元人民幣收購正大天晴5%股權，對應市盈率19倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1164324018","media":"美股速递","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164324018?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 16:31","pubTimestamp":1789115473,"startTime":"0","endTime":"0","summary":"中国生物制药宣布，其附属公司SBP集团将斥资44.8亿元人民币，用以收购正大天晴5%的股权权益。此项交易的定价依据为过去十二个月市盈率约19倍，反映出公司对正大天晴未来盈利潜力的充足信心。据悉，此次股权收购将进一步巩固中国生物制药在正大天晴中的股东地位，并有望深化双方在医药研发、生产及市场拓展等方面的战略协同效应。交易完成后，中国生物制药在正大天晴的持股比例将有所提升，预计将对集团的合并报表利润产生积极影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01177","BK1589","BK1521","IE00BZ08YT58.USD","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1515","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666546476","title":"同源康醫藥－Ｂ(02410)股價上升8.209%，現價港幣$2.9","url":"https://stock-news.laohu8.com/highlight/detail?id=2666546476","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666546476?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 14:05","pubTimestamp":1789106700,"startTime":"0","endTime":"0","summary":"[上升股]同源康医药－Ｂ(02410) 股价在下午02:04比前收市价上升8.209%，现股价为港币$2.9。至目前为止，今日最高价为$2.99，而最低价为$2.515。总成交量为613.95万股，总成交金额为港币$1.711千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609111558/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609111558/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["159938","BK1574","BK1515","09939","BK1161","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666545362","title":"同源康醫藥-B(02410)：短期股價波動無礙長期邏輯，大股東增持疊加穩中向好基本面打開配置空間","url":"https://stock-news.laohu8.com/highlight/detail?id=2666545362","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666545362?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 13:13","pubTimestamp":1789103634,"startTime":"0","endTime":"0","summary":"近期，在基本面稳中向好、核心品种顺利获批附条件上市、大股东大幅增持情况下，同源康股价却在外部因素与短期市场情绪影响下“砸出洼地”，而这也为长期价值投资者留出了潜在的布局机会。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260911/20260911131405_46437.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260911/20260911131405_46437.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1515","BK1574","159938","02410","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666548003","title":"京東打造中國服務第一品牌 助力中國企業融入全球產業鏈","url":"https://stock-news.laohu8.com/highlight/detail?id=2666548003","media":"同花顺","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666548003?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 11:51","pubTimestamp":1789098660,"startTime":"0","endTime":"0","summary":"9月9日至13日，2026年中国国际服务贸易交易会在北京首钢园举办，吸引来自全球90个国家、地区和国际组织参展、参会。京东已连续第七年参加服贸会，今年以“出海”为主线，围绕国际业务、全球 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260911/c679820138.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260911/c679820138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["07618","BK1583","JD","LU0307460666.USD","LU1688375341.USD","BK4526","BK4585","BK4122","BK1151","LU0326950275.SGD","86618","HK0000320264.USD","BK1604","02618","LU0456827905.SGD","LU1880383366.USD","SGXZ86797644.SGD","LU0051755006.USD","HK0000306701.USD","BK4531","BK1124","BK4558","IE0008368742.USD","BK1541","BK1247","BK1589","IE00BGV7N243.SGD","SG9999002463.SGD","BK4220","LU1188198961.HKD","06618","BK4551","SGXZ62798434.SGD","KJD","BK1615","HK0000306685.HKD","BK1571","BK4614","LU0244354667.USD","BK4505","BK1502","BK4504","BK1515","09618","BK4588","LU0588546209.SGD","BK4503","LU0463099449.HKD","BK4579","BK1591","LU0106959298.USD","BK1142","BK4509","HK0000320223.HKD","BK4524","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666510786","title":"港股異動 | 創新藥概念股持續調整 海外利率預期反覆 2026國談收官進入結果等待期","url":"https://stock-news.laohu8.com/highlight/detail?id=2666510786","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666510786?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 11:08","pubTimestamp":1789096112,"startTime":"0","endTime":"0","summary":"消息面上，2026国谈现场谈判和价格协商收官，正式进入结果等待期。新版国家基本医保药品目录与商保创新药目录预计11月正式公布，2027年1月1日起统一执行。此外，能源供给风险急剧升温，10年期美债收益率攀升至近三年高位，市场定价美联储下周加息25BP的概率已升至约70%。分析人士指出，近期创新药板块的调整，主要受到海外利率预期反复、油价上行推升通胀担忧、临床风险事件扰动及资金风格轮动等因素影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","IE0008368742.USD","LU1960683339.HKD","LU0880133367.SGD","LU2097828557.USD","01093","MCRO","LU2097828474.EUR","LU0326950275.SGD","BK4585","IBBQ","LU1226287792.SGD","BK1589","LU2328871848.SGD","VXUS","LU0072913022.USD","01801","BK1161","LU1969619763.USD","IE0008369823.USD","06978","LU2488822045.USD","KURE","LNGR","IE00BZ08YT58.USD","KCAI","LU1831875114.USD","159992","LU0455707207.USD","LU2097828805.USD","LU0067412154.USD","MEDX","LU2242644610.SGD","LU0501845795.SGD","WRTH","LU1226288170.HKD","BK1515","02157","IE00B5MMRT66.SGD","LU1188198961.HKD","LU0244354667.USD","LU1328277881.USD","LU1807302812.USD","09995","LU1226287875.USD","LU1813983027.USD","LU0149534421.HKD","PEVC","LU1008478684.HKD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666510406","title":"港股異動 | 同源康醫藥-B(02410)升逾9% 董事長增持彰顯長期發展信心 創新EGFR-TKI 重磅獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2666510406","media":"智通财经","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666510406?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 11:01","pubTimestamp":1789095677,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B今早拉升逾9%，截至发稿，涨9.7%，报2.94港元，成交额963.22万港元。消息面上，同源康医药昨晚公布，董事长、执行董事兼总裁吴豫生告知，于本月8至10日期间，于公开市场购入63.5万股H股，占已发行股本总额约0.17%，总代价约209万港元。公司表示，吴豫生已告知未来可能继续根据市场情况购买股份。此次进一步增持股份彰显对集团未来发展前景的信念及充分信心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1515","KCAI","VXUS","BK1574","BK4588","159938","BK1161","02410","09939"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":1,"totalSize":219,"code":"91000000","status":"200"}]}}